Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.

dc.contributor.author	Hoyle, M
dc.contributor.author	Anderson, R
dc.date.accessioned	2013-10-02T11:26:41Z
dc.date.issued	2010-07
dc.description.abstract	Most health technology economic evaluations simulate only the prevalent cohort or the next incident cohort of patients. They therefore do not capture all future patient-related benefits and costs.	en_GB
dc.identifier.citation	Medical Decision Making, 2010, Vol. 30, Issue 4, pp. 426 - 437	en_GB
dc.identifier.doi	10.1177/0272989X09353946
dc.identifier.uri	http://hdl.handle.net/10871/13742
dc.language.iso	en	en_GB
dc.publisher	Sage Publications	en_GB
dc.relation.url	http://www.ncbi.nlm.nih.gov/pubmed/20228287	en_GB
dc.relation.url	http://mdm.sagepub.com/content/30/4/426	en_GB
dc.subject	Cohort Studies	en_GB
dc.subject	Cost-Benefit Analysis	en_GB
dc.subject	Humans	en_GB
dc.title	Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.	en_GB
dc.type	Article	en_GB
dc.date.available	2013-10-02T11:26:41Z
dc.identifier.issn	0272-989X
exeter.place-of-publication	United States
dc.description	The final version of this paper has been published in Medical Decision Making, Vol 30 Issue 4, Jul/Aug 2010 by SAGE Publications Ltd, All rights reserved. © Martin Hoyle, 2010. It is available at: http://mdm.sagepub.com/content/30/4/426	en_GB
dc.identifier.journal	Medical Decision Making	en_GB